CAMLINFINE - Camlin Fine Sciences Ltd Share Price

Chemicals & Petrochemicals

₹163.07-0.56(-0.34%)

Market Closed as of Apr 29, 2025, 15:30 IST

What does Camlin Fine Sciences Ltd do?

Specialty Chemicals•Chemicals•Small Cap

Camlin Fine Sciences Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include antioxidants comprises Butylated Hydroxy Toluene and Ascorbyl palmitate; and emulsifiers, mold inhibitors, antibacterial agents, toxin binders, pellet binders, disinfectants, energizers, preservatives, thickening agents, and growth promoters, as well as plant-based antioxidants, such as mixed tocopherols, green tea extract, and rosemary extract that are used to enhance the shelf life under the Xtendra and NaSure brands. It also provides aroma ingredients, including vanillin and ethyl vanillin; health and wellness products; and performance chemicals, such as hydroquinone and catechol. Its products are used in food and beverage, pet food, animal nutrition, rendering, health and wellbeing, chemicals, biofuel, aroma technical, fragrance, and flavor industries. The company was formerly known as Camlin Fine Chemicals Limited and changed its name to Camlin Fine Sciences Limited in August 2011. Camlin Fine Sciences Limited was founded in 1931 and is headquartered in Mumbai, India.

Industry Group:Chemicals & Petrochemicals

Employees:624

Website:www.camlinfs.com

Investor Care
Shares Dilution (1Y)	12.22%
Diluted EPS (TTM)	-12.76

Financial Health
Current Ratio	1.2
Debt/Equity	1.11

Summary of Latest Earnings Report from Camlin Fine Sciences

Summary of Camlin Fine Sciences's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated: Feb 25

Management Outlook and Major Points:

1. Financial Performance & Growth:

Revenue & Margins: Q3 revenue rose 2% YoY to Rs.433.5 crores, with gross margin improving to 50% (up from 48%) and EBITDA margin increasing to 12% (vs. 10%). Management expects gradual stabilization amid global economic challenges.
Debt & Liquidity: Repaid Rs.100 crore NCD using proceeds from a recent rights issue (Rs.224 crores). Gross debt remains ~Rs.600 crores, with annual repayments of Rs.45"“50 crores planned.

2. Vanillin Business:

Capacity Utilization: Targeting 70% utilization at Dahej plant by FY25-end, scaling to 75% in FY26. Full capacity (6,000 tons) could generate Rs.600"“700 crore revenue annually.
Pricing & Demand: Anti-dumping duties in the US and proposed duties in Europe are boosting prices (current US prices: ~$12"“13/kg). Prices expected to rise 10"“15% as markets stabilize.
Breakeven: Vanillin + Catechol chain to breakeven at 70% utilization, with EBITDA margin improvement anticipated.

3. Blends Business:

Growth: Consistently growing at 15"“20% annually, driven by new customer acquisitions and geographic expansion (Americas, India). Gross margins ~35%.
Vitafor Integration: Acquisition to enhance presence in animal feed blends; EBITDA breakeven achieved, with 20"“25% growth targeted in FY26.

4. Cost Rationalization:

Europe Operations: Quarterly loss of Rs.16 crores to reduce significantly by Q1 FY26 (annual loss target: Rs.20"“25 crores vs. ~Rs.55 crores currently).
China Operations: Quarterly loss of Rs.3"“4 crores to improve in FY26.

5. Future Focus:

Verticals: Prioritize Vanillin (expand product portfolio, including natural variants), Blends (technical innovation), and antioxidants (BHA/BHT).
Geographies: Balanced exposure to US (anti-dumping benefits), Europe, and RoW.

6. Guidance:

FY26 EBITDA: Expected improvement from higher Vanillin pricing/utilization and reduced European losses. Blends to sustain 15"“20% growth.
CAPEX: Rs.30"“35 crores allocated for maintenance and minor expansions.

Q&A Session

Last updated: Feb 25

Question 1:
Tushar Raghatate (Kamayakya Wealth Management): Sir, like in the last call, you guided for 75% utilization of your Vanillin plant for FY26. Got it, sir. Sir, so like in terms of improving the realization for FY26, I am asking, do you see the margin to improve now sequentially and YOY going forward?

Answer: The 75% utilization guidance for FY26 remains. Margins are expected to improve with rising prices due to anti-dumping actions, though exact pricing trends remain uncertain.

Question 2:
Satish Kumar (InCred Research): Good evening sir, I just wanted to know what has been our fixed cost in European operations this quarter?

Answer: Fixed costs for European operations were ~Rs.16 crores this quarter and will reduce significantly from Q1FY26 after evacuating intermediate materials.

Question 3:
Shubham Jain (NV Alpha Funds): What is the total loss that we are still making in the Catechol plus Vanillin combined entity at a quarter level?

Answer: The Catechol-Vanillin chain will breakeven at ~70% Vanillin utilization (expected by FY26). Vanillin alone breakeven is at ~40% utilization.

Question 4:
Ravi Mehta (Deep Financials): Q4 is basically will have a better pricing compared to Q3?

Answer: Yes, Q4 pricing is improving post-US anti-dumping duty, with gradual recovery across markets.

Question 5:
Raman KV (Sequent Investments): What is the current capacity utilization for Catechol and Vanillin?

Answer: Diphenol (Catechol) plant: ~75% utilization, targeting 85"“90% by year-end. Vanillin: ~50"“55% utilization, ramping to 70% by FY25 end.

Question 6:
Jatin Sangwan (Burman Capital): What is EBITDA from continuing operations (excluding Europe/China losses)?

Answer: Adjusted EBITDA from continuing operations is ~Rs.70 crores (vs. reported Rs.53 crores after including Rs.17 crores losses from discontinued ops).

Question 7:
Surya Patra (PhillipCapital): What is the visibility for Vanillin volume ramp-up in FY26?

Answer: Limited long-term contracts due to price volatility, but structured regional diversification (1/3 each to US, Europe, ROW) supports utilization.

Question 8:
Rahul Picha (Multi Act): What is the debt repayment plan and FY26 capex?

Answer: Repaying Rs.45"“50 crores annually; gross debt at Rs.600 crores post-rights issue. FY26 capex: Rs.30"“35 crores (mainly maintenance).

Question 9:
Nisarg Vakharia (NV Alpha Fund Management): What are Blends' gross margins and working capital needs?

Answer: Blends' gross margins: 30"“35%. Working capital: 100"“110 days (inventory + receivables).

Question 10:
Prashant Kothari (Stock Market Read): How has Vitafor integration progressed? Impact of US-Mexico tariffs?

Answer: Vitafor integration complete; targeting 20"“25% growth in FY26. Mexico operations unaffected by tariffs (negotiations ongoing).

Question 11:
Parthiv Shah (TS Builders): What drives Blends' 20% growth vs. global peers?

Answer: Growth driven by technical expertise, customer acquisition, and geographic expansion. Focus on human/animal food blends.

Question 12:
Tushar Raghatate (Follow-up): Post-H2FY26 margin outlook?

Answer: Margins uncertain due to pricing dynamics but likely to improve as discontinued ops (Europe/China) wind down.

Question 13:
Jatin Sangwan (Follow-up): Vanillin cost reduction at higher utilization?

Answer: At 100% utilization, Vanillin production cost could drop ~10% (from $8.50"“9.00/kg to ~$8.00/kg).

Question 14:
Surya Patra (Follow-up): Debt details post-rights issue?

Answer: Gross debt at Rs.600 crores post-repayment of Rs.100 crores NCD. No immediate plans for accelerated repayment.

Question 15:
Rahul Picha (Follow-up): Europe/China loss reduction timeline?

Answer: Europe losses to reduce to Rs.20"“25 crores annually by FY26; China losses at Rs.3"“4 crores/quarter, improving next year.

Question 16:
Nisarg Vakharia (Follow-up): Why not disclose Catechol loss separately?

Answer: Catechol is a joint product; losses offset by Hydroquinone profits. Minimal standalone Catechol sales.

Question 17:
Raman KV (Follow-up): Use of rights issue proceeds?

Answer: Rs.100 crores repaid for NCD, Rs.68 crores reserved for debt repayment, Rs.56 crores for general purposes.

Question 18:
Parthiv Shah (Follow-up): Vanillin capacity de-bottlenecking?

Answer: Max capacity: ~7,000 tons post-de-bottlenecking. FY26 target: 75% utilization (4,500 tons), 100% in later years.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Category	CAMLINFINE	Chemicals
PE	-12.81	54.24
PS	1.84	4.56
Growth	1.5 %	7.3 %

Valuation
Market Cap	3.06 kCr
Price/Earnings (Trailing)	-12.77
Price/Sales (Trailing)	1.83
EV/EBITDA	-36.98
Price/Free Cashflow	23.09
MarketCap/EBT	-11.86

Fundamentals
Revenue (TTM)	1.68 kCr
Rev. Growth (Yr)	12.2%
Rev. Growth (Qtr)	-0.06%
Earnings (TTM)	-240.01 Cr
Earnings Growth (Yr)	47.67%
Earnings Growth (Qtr)	93.57%

Profitability
Operating Margin	-3.43%
EBT Margin	-15.42%
Return on Equity	-36.08%
Return on Assets	-12.73%
Free Cashflow Yield	4.33%

Income Statement for Camlin Fine Sciences

Standalone figures (in Rs. Crores) / View Consolidated Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	-9.7%	205	227	182	220	186	206
Other Income	179.8%	6.82	3.08	1.78	5.55	2.13	5.63
Total Income	-7.9%	212	230	184	226	188	212
Cost of Materials	-30%	106	151	132	108	104	113
Purchases of stock-in-trade	-104%	0.48	14	2.26	3.88	1.02	2.65
Employee Expense	-15.8%	17	20	17	17	16	18
Finance costs	-5.9%	17	18	14	14	13	15
Depreciation and Amortization	0%	13	13	13	13	12	12
Other expenses	11.3%	70	63	56	64	56	59
Total Expenses	-10.3%	219	244	201	273	205	212
Profit Before exceptional items and Tax	46.4%	-7.19	-14.27	-17.6	-46.75	-17.69	-0.52
Exceptional items before tax	99%	0	-96.27	0	-1.93	0	0
Total profit before tax	92.7%	-7.19	-110.54	-17.6	-48.68	-17.69	-0.52
Current tax	-122.5%	0	5.44	-3.78	-0.63	-1.33	0.2
Deferred tax	94.2%	-1.57	-43.36	-0.13	-3.98	-4.72	0.74
Total tax	93.4%	-1.57	-37.91	-3.92	-4.61	-6.05	0.93
Total profit (loss) for period	91%	-5.63	-72.62	-13.68	-44.07	-11.64	-1.46
Other comp. income net of taxes	-93%	-2.32	-0.72	0.55	-0.22	-0.09	-1.04
Total Comprehensive Income	88%	-7.95	-73.34	-13.13	-44.3	-11.73	-2.5
Earnings Per Share, Basic	75.1%	-0.33	-4.34	-0.82	-2.65	-0.7	-0.09
Earnings Per Share, Diluted	74.9%	-0.327	-4.29	-0.81	-2.61	-0.69	-0.09

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2018
Revenue From Operations	-2%	773	789	686	600	580	405
Other Income	-35.7%	19	29	19	5.47	24	9.23
Total Income	-3.2%	792	818	704	606	604	414
Cost of Materials	5.7%	426	403	382	384	377	260
Purchases of stock-in-trade	64.3%	8.46	5.54	7.62	16	13	24
Employee Expense	10.2%	66	60	53	39	28	21
Finance costs	-5.4%	54	57	33	33	28	24
Depreciation and Amortization	50%	49	33	27	19	11	9.06
Other expenses	0.4%	237	236	161	121	103	74
Total Expenses	13%	850	752	668	590	559	432
Profit Before exceptional items and Tax	-188.9%	-57.7	67	36	16	44	-18.07
Exceptional items before tax	-	-1.93	0	0	-0.5	-3.14	0
Total profit before tax	-191.9%	-59.63	67	36	15	41	-18.07
Current tax	-107.7%	0	14	6.4	2.78	7.5	0
Deferred tax	-322.7%	-8.24	5.15	3.81	3.96	3.06	-3.89
Total tax	-151.3%	-8.24	19	10	6.74	11	-3.89
Total profit (loss) for period	-211.5%	-51.39	48	26	8.28	31	-14.18
Other comp. income net of taxes	37.3%	-0.04	-0.66	-0.15	-0.38	-0.29	0.12
Total Comprehensive Income	-214%	-51.43	47	26	7.9	30	-14.05
Earnings Per Share, Basic	-287.6%	-3.09	3.18	1.98	0.67	2.53	-1.67
Earnings Per Share, Diluted	-289.3%	-3.05	3.14	1.94	0.6	2.53	-1.63

Consolidated figures (in Rs. Crores) / View Standalone Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	2.4%	433	423	396	402	386	406
Other Income	-96.9%	1.34	12	1.87	5.76	1.66	1.76
Total Income	0%	435	435	398	407	388	408
Cost of Materials	-22.5%	173	223	215	137	156	206
Purchases of stock-in-trade	-17%	45	54	16	43	39	12
Employee Expense	0%	52	52	51	46	45	43
Finance costs	32%	34	26	23	16	14	20
Depreciation and Amortization	-35%	14	21	20	20	21	19
Other expenses	7.5%	116	108	108	107	104	114
Total Expenses	1.4%	433	427	421	451	397	420
Profit Before exceptional items and Tax	-92.8%	1.52	8.23	-23.48	-43.7	-9.73	-12.09
Exceptional items before tax	99.3%	0	-151.04	0	-49.8	0	0
Total profit before tax	100.4%	1.52	-142.81	-23.48	-93.51	-9.73	-12.09
Current tax	-77.9%	4.32	16	7.4	6.51	6.48	7.86
Deferred tax	104.2%	2.82	-42.61	3.77	-18.23	-1.94	0.89
Total tax	122.6%	7.14	-26.2	11	-11.72	4.55	8.74
Total profit (loss) for period	92.8%	-7.47	-116.11	-34.65	-81.79	-14.28	-20.83
Other comp. income net of taxes	-1251.5%	-12.11	0.03	-5.95	-0.92	16	-2.48
Total Comprehensive Income	82.4%	-19.58	-116.08	-40.6	-82.71	2.11	-23.31
Earnings Per Share, Basic	82.2%	-0.243	-5.98	-2.03	-4.64	-0.71	-1.17
Earnings Per Share, Diluted	82.1%	-0.24	-5.93	-2.01	-4.58	-0.7	-1.16

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2018
Revenue From Operations	-4.1%	1,613	1,682	1,412	1,187	1,049	723
Other Income	212.5%	16	5.8	33	4.98	3.43	12
Total Income	-3.4%	1,629	1,687	1,445	1,192	1,053	734
Cost of Materials	-12.7%	747	856	728	488	500	385
Purchases of stock-in-trade	88.3%	114	61	45	78	53	31
Employee Expense	9.9%	179	163	145	120	100	73
Finance costs	3.5%	60	58	36	38	43	28
Depreciation and Amortization	25.8%	79	63	56	44	33	27
Other expenses	-10.6%	447	500	355	301	285	215
Total Expenses	5.1%	1,678	1,597	1,351	1,087	994	765
Profit Before exceptional items and Tax	-156.7%	-49.44	90	94	105	58	-30.9
Exceptional items before tax	-375.7%	-49.8	-9.68	0	0	0	0
Total profit before tax	-226.9%	-99.24	80	94	105	58	-30.9
Current tax	-14.3%	25	29	32	27	25	8.57
Deferred tax	-284%	-19.24	12	1.53	12	3.48	-15.33
Total tax	-88.4%	5.63	41	34	40	28	-6.75
Total profit (loss) for period	-371.5%	-104.88	40	60	65	30	-23.97
Other comp. income net of taxes	-10.5%	18	20	-7.77	114	1.3	12
Total Comprehensive Income	-249%	-86.91	60	53	179	31	-11.61
Earnings Per Share, Basic	-368.6%	-5.58	3.45	4.65	4.13	2.5	-0.38
Earnings Per Share, Diluted	-369.7%	-5.5	3.41	4.56	3.68	2.5	-0.37

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
VINATIORGA	Vinati OrganicsSpecialty Chemicals	17.12 kCr	2.2 kCr	+4.44%	+0.65%	44.3	7.79	+16.41%	+7.41%
JUBLINGREA	Jubilant IngreviaSpecialty Chemicals	10.42 kCr	4.24 kCr	+0.67%	+20.42%	50.5	2.46	-0.03%	+0.20%
GALAXYSURF	Galaxy SurfactantsSpecialty Chemicals	7.53 kCr	4.05 kCr	+3.65%	-17.36%	24.56	1.86	+4.96%	-2.53%
BALAMINES	Balaji AminesSpecialty Chemicals	4.2 kCr	1.49 kCr	+7.26%	-41.22%	22.01	2.81	-13.51%	-11.35%
SEQUENT	Sequent ScientificPharmaceuticals	3.66 kCr	1.53 kCr	+11.64%	+15.59%	157.88	2.39	+10.41%	+118.77%

Share Holdings

Understand Camlin Fine Sciences ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

As of 2025-03-31

Shareholder Name	Holding %
Ashish Subhash Dandekar	10.52%
Infinity Direct Holdings	10.41%
Anfima Nv	9.03%
Infinity Holdings	6.34%
Infinity Direct Holdings Sidecar I	4.93%
Camart Finance Limited	2.83%
Icici Prudential Smallcap Fund	2.69%
Nirmal Vinod Momaya	1.92%
Anagha Subhash Dandekar	1.61%
Vibha Agencies Pvt Ltd	1.39%
Ajay Upadhyaya	1.3%
Infinity Portfolio Holdings	1.2%
Jagdish N Master	1.08%
Urjita J Master	1.08%
Cafco Consultants Limited	0.8%
Radha Pandit	0.04%
Anand Y Pandit	0.01%
MK Falcon Agro tech Pvt. Ltd.	0%
Director or Director's Relatives	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Balance Sheet for Camlin Fine Sciences

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	-140.6%	0.23	0.68	0.14	22	16	22
Loans, current	9.8%	57	52	43	30	33	30
Total current financial assets	-19.1%	471	582	564	549	613	549
Inventories	-1.2%	252	255	281	142	174	142
Total current assets	-12.8%	748	858	864	718	811	718
Property, plant and equipment	-7.9%	516	560	564	282	285	251
Capital work-in-progress	-23.3%	24	31	35	207	321	207
Investment property	-	0	0	0	0	0	0
Non-current investments	-20.3%	64	80	82	82	82	82
Loans, non-current	-127.1%	0	4.69	12	6.8	8.73	6.8
Total non-current financial assets	-24.1%	67	88	98	95	95	95
Total non-current assets	-0.7%	706	711	724	625	729	625
Total assets	-7.4%	1,456	1,572	1,590	1,346	1,542	1,346
Borrowings, non-current	-12.2%	195	222	237	258	257	258
Total non-current financial liabilities	-17.8%	195	237	252	268	266	268
Provisions, non-current	11.8%	5.44	4.97	4.65	3.32	3.47	3.32
Total non-current liabilities	-14.1%	214	249	272	282	285	283
Borrowings, current	16.4%	313	269	244	190	307	189
Total current financial liabilities	-2.6%	565	580	506	442	602	441
Provisions, current	5.4%	3.13	3.02	2.48	1.7	1.33	1.7
Current tax liabilities	-	0.01	0	6.25	5.62	12	5.62
Total current liabilities	1%	613	607	546	472	639	470
Total liabilities	-3.5%	826	856	818	754	924	754
Equity share capital	0%	17	17	17	16	16	16
Total equity	-12%	630	716	772	592	618	592
Total equity and liabilities	-7.4%	1,456	1,572	1,590	1,346	1,542	1,346

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	0%	80	80	92	94	86	108
Loans, current	-85.2%	2.33	10	10	10	0.06	0.08
Total current financial assets	6.2%	415	391	358	418	451	449
Inventories	-2.3%	501	513	591	568	433	371
Total current assets	2%	1,019	999	1,047	1,086	944	891
Property, plant and equipment	-23%	583	757	780	794	505	482
Capital work-in-progress	-53.3%	22	46	50	41	330	215
Investment property	-	0	0	0	0	0	0
Goodwill	63%	76	47	53	53	53	53
Non-current investments	219.8%	23	7.88	7.88	7.96	7.23	7.23
Total non-current financial assets	76.2%	38	22	22	25	22	25
Total non-current assets	-9.2%	864	951	965	972	981	907
Total assets	-3.4%	1,885	1,952	2,014	2,060	1,927	1,800
Borrowings, non-current	2.4%	341	333	351	408	369	388
Total non-current financial liabilities	-2.6%	341	350	369	423	402	405
Provisions, non-current	11.7%	5.59	5.11	4.77	4.81	3.47	3.32
Total non-current liabilities	1.9%	369	362	390	443	421	440
Borrowings, current	22.8%	399	325	315	371	370	235
Total current financial liabilities	13.5%	783	690	628	730	693	544
Provisions, current	4.9%	10	9.58	9.45	10	8.2	9.47
Current tax liabilities	242%	2.15	0.19	6.9	14	13	6.54
Total current liabilities	16.3%	851	732	681	793	745	595
Total liabilities	11.4%	1,220	1,095	1,071	1,236	1,166	1,035
Equity share capital	0%	17	17	17	16	16	16
Non controlling interest	-189.4%	-24.47	-7.8	-0.76	4.71	11	17
Total equity	-22.4%	665	857	942	824	761	765
Total equity and liabilities	-3.4%	1,885	1,952	2,014	2,060	1,927	1,800

Cash Flow for Camlin Fine Sciences

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	-5.4%	54	57	33
Change in inventories	-	-41.67	0	0
Depreciation	50%	49	33	27
Unrealised forex losses/gains	128.1%	6.68	-19.23	-5.75
Adjustments for interest income	20.6%	4.74	4.1	4.11
Share-based payments	-174.6%	0	2.34	7.36
Net Cashflows from Operations	296%	100	26	48
Income taxes paid (refund)	166%	18	7.39	1.15
Net Cashflows From Operating Activities	350%	82	19	47
Cashflows used in obtaining control of subsidiaries	-	0	0	6.55
Proceeds from sales of PPE	-	0.08	0	0
Purchase of property, plant and equipment	-69.2%	41	131	189
Interest received	-37.1%	0.52	0.65	1.61
Other inflows (outflows) of cash	-131.4%	-7.8	29	28
Net Cashflows From Investing Activities	54.4%	-51.72	-114.73	-172.33
Proceeds from issuing shares	-	0	0	95
Proceeds from exercise of stock options	6.7%	0.58	0.55	0
Proceeds from borrowings	-89.2%	14	121	88
Repayments of borrowings	-	1.4	0	21
Payments of lease liabilities	-133.6%	0	3.98	2.25
Interest paid	21.1%	47	39	31
Net Cashflows from Financing Activities	-145.5%	-34.05	78	129
Net change in cash and cash eq.	75.2%	-3.67	-17.82	3.39

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	3.5%	60	58	36
Depreciation	25.8%	79	63	56
Impairment loss / reversal	-111.5%	0	9.68	0
Unrealised forex losses/gains	464.4%	37	-8.88	-16.96
Adjustments for interest income	185.2%	1.23	0.73	1.56
Share-based payments	-172.8%	0.01	2.36	7.39
Net Cashflows from Operations	165.7%	187	71	176
Income taxes paid (refund)	147.4%	48	20	30
Net Cashflows From Operating Activities	176%	139	51	145
Cashflows used in obtaining control of subsidiaries	-	0	0	66
Proceeds from sales of PPE	-340%	0.56	0.9	0
Purchase of property, plant and equipment	-58%	61	144	214
Interest received	185.2%	1.23	0.73	1.7
Other inflows (outflows) of cash	-131.1%	-7.71	29	28
Net Cashflows From Investing Activities	46.3%	-66.5	-124.63	-249.13
Proceeds from issuing shares	-	0	0	95
Proceeds from exercise of stock options	6.7%	0.58	0.55	0
Proceeds from borrowings	-70%	25	81	106
Repayments of borrowings	98.1%	0	-52.27	30
Payments of lease liabilities	38.5%	11	8.22	8.83
Interest paid	41.2%	73	52	25
Other inflows (outflows) of cash	-96.2%	-28.13	-13.85	-0.71
Net Cashflows from Financing Activities	-247.4%	-85.97	60	136
Net change in cash and cash eq.	3.8%	-13.49	-14.07	32

CAMLINFINE - Camlin Fine Sciences Ltd Share Price

What does Camlin Fine Sciences Ltd do?

Investor Care

Financial Health

Summary of Latest Earnings Report from Camlin Fine Sciences

Sector Comparison: CAMLINFINE vs Chemicals & Petrochemicals

Comparative Metrics

Performance Comparison

Valuation

Fundamentals

Profitability

Income Statement for Camlin Fine Sciences

Is Camlin Fine Sciences Better than it's peers?

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

Balance Sheet for Camlin Fine Sciences

Cash Flow for Camlin Fine Sciences